Between 1980 and 1996, we transplanted 72 patients with CML using blood stem cells collected at diagnosis before treatment and without any mobilization. The median age of patients at diagnosis was 47.5 years (range 20.5-59.5). The median numbers of nucleated cells and CFU-GM transplanted were 10 ؋ 10 8 /kg and 97 ؋ 10 4 /kg, respectively. The median duration to reach more than 0.5 ؋ 10 9 /l neutrophils and 50 ؋ 10 9 /l platelets was 12 (range 5-19) and 11 days (range 0-79), respectively. Twenty patients (group I) were transplanted in chronic phase either for resistance to IFN (14 patients) (group IA) or because the Sokal index was more than 1.2 (six patients) (group IB). All those patients had preparative regimen with busulfan (4 mg/kg/day ؋ 4) and melphalan (140 mg/m 2 ). They were treated with recombinant alpha-interferon (IFN) after transplant. The cumulative incidence of major cytogenetic response (MCR) at 12 months was 25 ؎ 21% (95% CI), the 5-year survival was 75 ؎ 42% (95% CI). These results (observed in patients with bad prognosis factors) are similar to those usually observed in CML patients treated by IFN, whatever the Sokal risk. Thus autologous transplantation is able to reproduce for poor prognosis patients the results observed in standard risk patients treated with IFN. This suggests that it could prolong survival. Fifty-two other patients (group II) were transplanted for CML in transformation (accelerated phase = 32; blast crisis = 20) after a preparative regimen containing either total body irradiation (TBI) or busulfan. The median survival was short (10.4 months) and only 21 patients survived more than 1 year. The survival was longer for patients transplanted in accelerated phase (vs blast crisis), those who were due to receive a double transplant (vs single) (34 patients), those who were treated with IFN after transplant (vs hydroxyurea) and for the patients who obtained a complete hematologic response.
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by the presence of a chromosomal marker, the Philadelphia chromosome (Ph), which is the result of breaks on chromosome 9 and 22 with a reciprocal translocation. CML initially starts with a chronic (or indolent) phase whose median duration is approximately 3-4 years, then progresses to acceleration and blastic phase leading to death within about 6 months.
Allogeneic bone marrow transplantation (alloBMT) is the only curative treatment for CML. However, as alloBMT is usually restricted to patients under the age of 50 years with an HLA-identical donor, only a small proportion of patients with CML can benefit from it. 1 Recombinant alphainterferon (IFN) is able to induce a 15-30% rate of cytogenetic response and probably a prolongation of survival. [2] [3] [4] [5] Thus, alternative treatments have to be proposed for patients who either cannot undergo alloBMT or do not respond to IFN.
Autologous stem cell transplantation (ASCT) was first used to treat patients in transformation. Most patients achieved a second chronic phase but had recurrent transformation within 1 year after transplant. 6, 7 However, some exhibited a cytogenetic conversion and seemed to survive longer than the others. Thus, ASCT was proposed for patients in chronic phase. The preliminary results indicate that a prolongation of survival is possible. [8] [9] [10] We report here our results with 72 patients who underwent ASCT for bad prognosis CML at a single institution. All were unsuitable for allogeneic BMT as they were older than 50 years or did not have an HLA-identical family donor. Twenty patients were transplanted in chronic phase (CML-CP) either for resistance to IFN (14 patients = group IA) or because the Sokal index was more than 1.2 (6 patients = group IB). Fifty-two other patients had ASCT for CML in transformation (accelerated phase (CML-AP) = 32; blastic phase (CML-BP) = 20).
Patients and methods

Patients
From 1980 to 1996, 72 patients with Philadelphia chromosome (Ph)-positive CML were transplanted, in a single center, at the haematology department of Haut-Lévêque Hospital (CHU Bordeaux, France). There were 31 men and 41 women. The median age at the time of autografting was 47.5 years with a range of 20.5-59.5 years. Twenty patients (group I) were transplanted for CML in chronic phase either for resistance to IFN, defined by no hematologic or cytogenetic response after 6 or 12 months of treatment, respectively (14 patients) (group IA) (seven low and seven intermediate sokal score) with a median interval between diagnosis and ASCT of 14.5 months (5-82), or were transplanted early (median = 3.5 months, range 1.5-9.5 months) because the Sokal index was more than 1.2 (six patients) (group IB). Fifty-two other patients (group II) were transplanted for CML in transformation (CML-AP = 32, CML-BP = 20) after a chronic phase lasting 30 months (median). Diagnosis of CML-AP required the presence in peripheral blood of у15% blasts, or у30% blasts plus promyelocytes, у20% basophils, thrombocytopenia of 100 ϫ 10 9 /l unrelated to chemotherapy, or cytogenetic clonal evolution.
11 CML-BP was defined by the presence of у30% blasts in the peripheral blood or bone marrow, or extramedullary blastic disease. 12 Main patient characteristics are summarized in Table 1 . Patients were managed in rooms equipped with high-efficiency particulate air filtration and given antibiotics, amphotericin, irradiated blood products and intravenous nutrition when indicated.
Source of stem cells
Blood stem cells were collected at diagnosis, before any treatment and without any mobilization. Four to six leukaphereses were usually performed per patient. 13 Harvested cells were subsequently frozen using dimethyl sulfoxide (DMSO, 10%) as a cryoprotective agent and stored in liquid nitrogen. For transplantation, two leukaphereses products were infused at least 24 h after the last dose of chemotherapy or radiotherapy.
Conditioning regimens
The 20 group I patients were conditioned with busulfan (4 mg/kg/day; 4 days) and melphalan (140 mg/m 2 ) as previously described.
14 The median numbers of nucleated cells and CFU-GM infused were 10.2 ϫ 10 8 /kg and 68.5 ϫ 10 4 /kg, respectively. For group II patients,the preparative regimen varied according to the time period of therapy: 7 13 patients received DAT (daunorubicin (60 2 /day × 5) ), followed by cyclophosphamide (60 mg/kg/day ϫ 2) and TBI; nine others received highdose cytarabine (3 g/m 2 /12 h ϫ 4), cyclophosphamide (60 mg/kg/day ϫ 2) and TBI; finally 27 patients received busulfan and melphalan as previously described, one patient received melphalan (200 mg/m 2 ) alone and two received high-dose cytarabine and melphalan. Thirty-four patients in group II were due to receive a double transplant. The second transplant was undertaken 3 months later, and conditioned with melphalan (140 mg/m 2 ) alone. Only 20 of the 34 patients had a second transplant, the other 14 patients being excluded from the second transplant for the following reasons: six patients were in 2nd TA at the time of the 2nd transplant, four had died before, three had heart or pulmonary injuries and one was in MCR.
The median numbers of nucleated cells and CFU-GM infused were 10. Only two patients had to stop IFN: one for retinopathy and the other for depression. Those who did not receive IFN were transplanted before 1986 and were treated with hydroxyurea when needed after ASCT (27 patients), or died or had a relapse soon after transplantation (seven patients).
Response criteria
Complete hematological response was defined as р5% blasts in a normocellular or hypercellular bone marrow, leukocytes 2 ϫ 10 9 /l to 10 ϫ 10 9 /l, no immature myeloid elements (blasts, promyelocytes and myelocytes), platelets у100 ϫ 10 9 /l and no extramedullary involvement. Cytogenetic analysis were performed on marrow cells using standard techniques, after re-establishment of the second CP and every 3-6 months. Cytogenetic response criteria were defined according to Talpaz et 
Statistical analysis
Patients were analyzed as intention to treat. The endpoint of the study was survival from ASCT. For statistical analysis, 2 was used to evaluate the significance of discontinued variables, and continued variables were analyzed using the Wilcoxon test in the different groups. Hematopoietic recovery, overall survival, cumulative incidences of hematologic and cytogenetic responses were analyzed by the Kaplan and Meier 16 method. The influence of prognostic factors was studied using the log rank test 17 (univariate) analysis, and the Cox regression model was used for multivariate analysis. Thus, for the 68 patients who survived more than 30 days after ASCT, engraftment was complete in all cases. Analysis of prognostic factors for engraftment showed that only the dose of CFU-GM significantly influenced platelet recovery (P = 0.02).
Results
Hematopoietic recovery
Hematologic and cytogenetic response
Group I: All patients achieved a complete hematologic response (CHR). The cumulative incidence of MCR at 12 months was 25 Ϯ 21% (95% CI). Five patients achieved a MCR (one CCR) and eight a minor cytogenetic response. For the 14 patients transplanted for resistance to IFN (group IA), four were previously in CHR at the time of transplant, the others obtained CHR after ASCT, four patients obtained a MCR (one CCR) and seven a minor cytogenetic response. For the six group IB patients: six obtained CHR, one MCR (0 CCR) and one a minor cytogenetic response. Group II: 15/52 achieved complete hematologic remission. The cumulative incidence of MCR at 12 months was 13 Ϯ 13% (95% CI). Three patients achieved a MCR (one CCR) and three a minor cytogenetic response.
For both groups MCR was achieved for only one patient already in CHR before transplant. Patients who entered CCR were not in CHR before transplant.
Overall survival
Group I: Three-year and 5-year survivals from the time of stem cell reinfusion were 100% and 75 Ϯ 42% (95% CI) respectively (Figure 1 ). For groups IA and IB, 5-year survival was respectively 100% and 66 Ϯ 54% (95% CI). The following factors did not significantly influence survival: age, sex, spleen size, white blood cell and platelet counts at diagnosis, Sokal score, interval between diagnosis and ASCT, type of conditioning regimen. However, there was a trend for a better survival in patients achieving MCR (P = 0.07).
Group II: Three-year survival from the time of stem cell reinfusion was 25 Ϯ 12% (95% CI) (Figure 2 ). For CML-AP and CML-BP, the 3-year survival was respectively 39 Ϯ 18% and 5 Ϯ 9% (95% CI). Survival was not influenced by the following prognostic factors: age, sex, spleen size, white blood cell and platelet counts at diagnosis, Sokal score, interval between diagnosis and ASCT or type of conditioning regimen. However, survival was statistically longer for patients achieving CHR (P = 0.0035) (Figure 2 ) and for patients who were treated with IFN post-transplant following consecutive transplantion, one from a second BP after ASCT and one from organ failure after allogeneic transplantation in second chronic phase (51-88 months after the first ASCT). Seventeen are still alive 3-73 months after ASCT (median 23.7 months). Fourteen of these patients belong to group IA and three to group IB. Of the 17 surviving patients, four (three group IA and one group IB) are still in MCR. Group II patients: 44 patients died: 13 died from transplantation (infectious disease four, interstitial pneumonitis four, encephalitis two, veno-occlusive disease one, pulmonary embolism one, extra-dural hematoma one), 24 died from transformation occurring within 7 months following ASCT (range 1.5-68 months), five died following a subsequent ASCT with a median of 14 months (1-95), two died following alloBMT performed in CP. Only eight patients are alive, six patients in CML-CP (one still in MCR) 1-82 months after ASCT (median 32 months) and two patients after subsequent ASCT.
Discussion
In our experience, ASCT in chronic phase CML is associated with very low toxicity as no group I patient died following transplantation. Our results are also encouraging as we observed 25% of major cytogenetic response and an overall survival at 5 years of 75 Ϯ 42%. This is better than the results observed for patients conventionally treated with busulfan or hydroxyurea. It is difficult to compare our results with other studies as there is a wide heterogeneity between the different studies concerning characteristics of patients and transplants. However, similar encouraging results have been reported in other unicentric studies as the achievement of a cytogenetic response varies from 23 to 64% and survival from 50 to 70% at 3-5 years. 8, 13, 18 This is also confirmed by multicentric studies. In the multicentric study reported by McGlave et al, 10 the survival of 142 patients undergoing ASCT in chronic phase was 60% at 5 years. In the EBMT retrospective analysis, the estimated chance of survival at 3 years was 81.5 Ϯ 13% (95% CI). 9 As no prospective study has compared ASCT with IFN, it is still unknown whether ASCT could prolong survival in CML, and if so in what category of patients. Thus, it seems essential to perform randomized studies to study prolongation of survival. In this perspective, we are involved in a phase III protocol (LMC 97) for newly diagnosed CML patients comparing ASCT followed by IFN + cytarabine vs IFN + cytarabine. The choice of IFN associated with cytarabine as reference protocol was made after the report by Guilhot et al. 19 In our study we observed a very good survival for group IA patients (IFN-resistant) as we observed no toxicity and a 5-year survival of 100%. Most patients (11/14) obtained a cytogenetic response and four achieved MCR. This suggests that ASCT could reverse the resistance to IFN. In the series of Khouri et al, 20 ASCT did not seem to prolong survival in these IFN-resistant patients, whereas in the EBMT retrospective analysis, some patients were restored to IFN sensitivity after ASCT. 21 Thus, the possible restoration of IFN sensitivity after ASCT needs to be further evaluated.
As for alloSCT, the results of ASCT for CML in transformation are very poor. Our results confirm a longer survival for patients transplanted in the accelerated phase rather than in blast crisis. The prognosis for patients evolving to the blastic phase remains poor, with a median survival of approximately 3-6 months. Response duration with ASCT in our study is extremely short with a median survival of 3.7 months. For CML-BP supportive care might be superior in terms of quality of life over any type of intensive treatment. For CML-AP there is probably a survival advantage for patients undergoing ASCT, especially for those who can receive a double transplant. Patients who received a double transplant had a longer survival than those with a single transplant (Figure 4 , P = 0.0014), and patients who received IFN post-transplant also had improved survival compared with those who did not (Figure 3 , P = 0.0014). Thus, the best strategy for patients in transformation is probably represented by a double transplant followed by IFN therapy.
It has been suggested that the results of ASCT could be improved by in vitro or in vivo purging methods. Retroviral marking studies have shown that Ph chromosome-positive CML cells remaining among the transplanted cells could contribute to relapse after transplantation. 22 Therefore, adequate purging procedures may be required to produce populations of cells that are free of Ph-positive cells. Several approaches have been proposed for in vitro purging to eradicate Ph-positive cells such as the use of derivatives of cyclophosphamide (Mafosfamide), 23 long-term culture techniques, 24 and use of gamma-interferon 25 or antisense oligonucleotides. 26, 27 These methods have given encouraging results in vitro but unfortunately their use does not seem to improve survival of patients when they are used in vivo. Moreover, in vivo methods such collection of normal blood repopulating cells during early hematopoietic recovery after intensive chemotherapy and G-CSF lead to a high rate of complete cytogenetic response after ASCT. 28, 29 These results are very encouraging but the procedurerelated mortality is sometimes high and could compromise the potential benefits. 30 No prolongation of survival has been observed to date, and a longer follow-up of the studies is required.
Many data indicate that ASCT can have a beneficial effect on survival in certain patients with CML. Since the toxicity of ASCT is low, this effect of ASCT needs to be further evaluated within the setting of prospective multicentric studies. In view of the recent biologic data allowing possible selection of normal cells in CML, the optimum conditions in which ASCT is to be performed could be further defined. The optimum timing of ASCT could be defined by using early indicators of IFN resistance, 5, 31 which might further enhance the results of ASCT.
